Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fortress Biotech (FBIO) Operating Income (2016 - 2025)

Fortress Biotech has reported Operating Income over the past 13 years, most recently at $58.4 million for Q4 2025.

  • For Q4 2025, Operating Income rose 345.07% year-over-year to $58.4 million; the TTM value through Dec 2025 reached -$7.2 million, up 93.48%, while the annual FY2025 figure was -$7.0 million, 93.64% up from the prior year.
  • Operating Income for Q4 2025 was $58.4 million at Fortress Biotech, up from -$6.8 million in the prior quarter.
  • Over five years, Operating Income peaked at $58.4 million in Q4 2025 and troughed at -$62.0 million in Q4 2021.
  • A 5-year average of -$32.4 million and a median of -$36.5 million in 2024 define the central range for Operating Income.
  • Biggest five-year swings in Operating Income: tumbled 155.12% in 2021 and later soared 345.07% in 2025.
  • Year by year, Operating Income stood at -$62.0 million in 2021, then grew by 11.88% to -$54.6 million in 2022, then skyrocketed by 64.1% to -$19.6 million in 2023, then decreased by 21.52% to -$23.8 million in 2024, then soared by 345.07% to $58.4 million in 2025.
  • Business Quant data shows Operating Income for FBIO at $58.4 million in Q4 2025, -$6.8 million in Q3 2025, and -$36.5 million in Q2 2025.